{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:55:49Z","timestamp":1790646949969,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","award":["Eli Lilly and Company"],"award-info":[{"award-number":["Eli Lilly and Company"]}],"id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014392","name":"Avid Radiopharmaceuticals","doi-asserted-by":"publisher","award":["Avid Radiopharmaceuticals"],"award-info":[{"award-number":["Avid Radiopharmaceuticals"]}],"id":[{"id":"10.13039\/100014392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      <jats:sup>18<\/jats:sup>\n                      F-flortaucipir (Tauvid\u2122) is an\n                      <jats:sup>18<\/jats:sup>\n                      F-labeled diagnostic positron emission tomography (PET) radiopharmaceutical, which was developed to detect tau pathology in the brain and to estimate the density and\/or distribution of aggregated tau neurofibrillary tangles for patients being evaluated for Alzheimer\u2019s disease (AD). The objective of this article is to report findings from two studies. The primary objective of the first\n                      <jats:italic>(<\/jats:italic>\n                      dose and biodistribution) study was to investigate the consistency of\n                      <jats:sup>18<\/jats:sup>\n                      F-flortaucipir PET biodistribution between Japanese and non-Japanese individuals. In the second (reader) study, the comparability of visual reads performed by Japanese and US expert readers who followed the same training program was evaluated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This article reports findings from two separate studies and datasets. In the dose and biodistribution study, whole-body distribution of\n                      <jats:sup>18<\/jats:sup>\n                      F-flortaucipir was assessed (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u20099). Standardized uptake value ratios, normalized to the entire cerebellum, were calculated, and whole-body effective dose was calculated using a 73.7\u00a0kg bodyweight model. In the reader study (Study A27; I7E-AV-A27), five Japanese physicians visually interpreted 60 PET scans randomly selected from a previous US reader study (Study FR01; NCT03901092). Scan positivity was determined based on increased activity of\n                      <jats:sup>18<\/jats:sup>\n                      F-flortaucipir in posterolateral temporal, occipital, or parietal\/precuneus regions with or without frontal activity. Each scan was visually interpreted by all Japanese readers, who determined whether scans were consistent with an AD or non-AD pattern. Concordance between Japanese and US readers who underwent the same training on the interpretation of\n                      <jats:sup>18<\/jats:sup>\n                      F-flortaucipir PET images was then evaluated (reader study primary endpoint).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The biodistribution of\n                      <jats:sup>18<\/jats:sup>\n                      F-flortaucipir was consistent between Japanese and non-Japanese individuals. When interpreting\n                      <jats:sup>18<\/jats:sup>\n                      F-flortaucipir PET images to distinguish between AD versus non-AD patterns, Japanese and US readers who underwent the same training showed 100% agreement on the majority reads, with a Cohen\u2019s Kappa value of 1.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      <jats:sup>18<\/jats:sup>\n                      F-flortaucipir whole-body biodistribution for Japanese individuals was consistent with that of non-Japanese individuals. After completing the same training, Japanese readers showed high concordance with US readers on the interpretation of\n                      <jats:sup>18<\/jats:sup>\n                      F-flortaucipir PET images to distinguish between AD and non-AD patterns. Data and scans were from previous studies registered with ClinicalTrials.gov (registration numbers: NCT04474405; NCT03901092).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12149-026-02239-4","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T11:43:54Z","timestamp":1784288634000},"page":"1219-1228","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["18F-flortaucipir PET imaging: Biodistribution in the Japanese population and diagnostic accuracy by Japanese readers"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1708-3618","authenticated-orcid":false,"given":"Etsuko","family":"Imabayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Iaccarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupa K.","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko","family":"Kamiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"issue":"2","key":"2239_CR1","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1093\/procel\/pwae026","volume":"16","author":"Q Zheng","year":"2025","unstructured":"Zheng Q, Wang X. Alzheimer\u2019s disease: insights into pathology, molecular mechanisms, and therapy. Protein Cell. 2025;16(2):83\u2013120.","journal-title":"Protein Cell"},{"key":"2239_CR2","doi-asserted-by":"crossref","unstructured":"Knopman DS, Amieva H, Petersen RC, Ch\u00e9telat G, Holtzman DM, Hyman BT, et al. Alzheimer disease. Nat Rev Dis Primers. 2021;7(1):33.","DOI":"10.1038\/s41572-021-00269-y"},{"key":"2239_CR3","doi-asserted-by":"crossref","unstructured":"Jack CR Jr., Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimers Dement. 2024;20(8):5143\u201369.","DOI":"10.1002\/alz.13859"},{"issue":"1","key":"2239_CR4","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/ana.24546","volume":"79","author":"KA Johnson","year":"2016","unstructured":"Johnson KA, Schultz A, Betensky RA, Becker JA, Sepulcre J, Rentz D, et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol. 2016;79(1):110\u20139.","journal-title":"Ann Neurol"},{"issue":"4","key":"2239_CR5","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/nrneurol.2018.9","volume":"14","author":"VL Villemagne","year":"2018","unstructured":"Villemagne VL, Dor\u00e9 V, Burnham SC, Masters CL, Rowe CC. Imaging tau and amyloid-\u03b2 proteinopathies in Alzheimer disease and other conditions. Nat Rev Neurol. 2018;14(4):225\u201336.","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"2239_CR6","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3390\/ph14020110","volume":"14","author":"CVML Jie","year":"2021","unstructured":"Jie CVML, Treyer V, Schibli R, Mu L. Tauvid\u2122: the first FDA-approved PET tracer for imaging tau pathology in Alzheimer\u2019s disease. Pharmaceuticals (Basel). 2021;14(2):110.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"2239_CR7","doi-asserted-by":"publisher","first-page":"fcad305","DOI":"10.1093\/braincomms\/fcad305","volume":"6","author":"SC Burnham","year":"2023","unstructured":"Burnham SC, Iaccarino L, Pontecorvo MJ, Fleisher AS, Lu M, Collins EC, et al. A review of the flortaucipir literature for positron emission tomography imaging of tau neurofibrillary tangles. Brain Commun. 2023;6(1):fcad305.","journal-title":"Brain Commun"},{"issue":"1","key":"2239_CR8","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3233\/JAD-130098","volume":"38","author":"DT Chien","year":"2014","unstructured":"Chien DT, Szardenings AK, Bahri S, Walsh JC, Mu F, Xia C, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. J Alzheimers Dis. 2014;38(1):171\u201384.","journal-title":"J Alzheimers Dis"},{"key":"2239_CR9","unstructured":"Eli Lilly and Company. TAUVID\u2122 (flortaucipir F 18 injection), for intravenous use [highlights of prescribing information]. https:\/\/pi.lilly.com\/us\/tauvid-uspi.pdf. Accessed 12 Jun 2025."},{"key":"2239_CR10","unstructured":"European Medicines Agency. Tauvid flortaucipir (18F). Accessed 12 Jun 2025. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tauvid"},{"key":"2239_CR11","unstructured":"Eli Lilly and Company. Tauvid 1 900 MBq\/mL solution for injection [summary of product characteristics]. https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/40278c788f4441b96ce5b225fe2b4a3bbf79f125. Accessed 17 Dec 2025."},{"issue":"6","key":"2239_CR12","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512\u201327.","journal-title":"JAMA"},{"key":"2239_CR13","unstructured":"PDRadiopharma Inc. TAUVID\u00ae Injection [package insert] [in Japanese]. https:\/\/www.pdradiopharma.com\/wpeptip\/wp-content\/uploads\/2025\/01\/TAU_PackageInserts.pdf. Accessed 10 Oct 2025."},{"key":"2239_CR14","doi-asserted-by":"crossref","unstructured":"Fleisher AS, Pontecorvo MJ, Devous MD Sr., Lu M, Arora AK, Truocchio SP, et al. Positron emission tomography imaging with [18F]flortaucipir and postmortem assessment of Alzheimer disease neuropathologic changes. JAMA Neurol. 2020;77(7):829\u201339.","DOI":"10.1001\/jamaneurol.2020.0528"},{"issue":"1","key":"2239_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","volume":"8","author":"BT Hyman","year":"2012","unstructured":"Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, et al. National Institute on Aging-Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease. Alzheimers Dement. 2012;8(1):1\u201313.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"2239_CR16","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1001\/jamaneurol.2020.5505","volume":"78","author":"M Lu","year":"2021","unstructured":"Lu M, Pontecorvo MJ, Devous MD, Sr., Arora AK, Galante N, McGeehan A, et al. Aggregated tau measured by visual interpretation of flortaucipir positron emission tomography and the associated risk of clinical progression of mild cognitive impairment and Alzheimer disease: results from 2 phase III clinical trials. JAMA Neurol. 2021;78(4):445\u201353.","journal-title":"JAMA Neurol"},{"issue":"1","key":"2239_CR17","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2307\/2529310","volume":"33","author":"JR Landis","year":"1977","unstructured":"Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159\u201374.","journal-title":"Biometrics"},{"issue":"1","key":"2239_CR18","doi-asserted-by":"publisher","first-page":"e14338","DOI":"10.1002\/alz.14338","volume":"21","author":"GD Rabinovici","year":"2025","unstructured":"Rabinovici GD, Knopman DS, Arbizu J, Benzinger TLS, Donohoe KJ, Hansson O, et al. Updated appropriate use criteria for amyloid and tau PET: a report from the Alzheimer\u2019s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup. Alzheimers Dement. 2025;21(1):e14338.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"2239_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-023-01160-6","volume":"15","author":"V Kotari","year":"2023","unstructured":"Kotari V, Southekal S, Navitsky M, Kennedy IA, Lu M, Morris A, et al. Early tau detection in flortaucipir images: validation in autopsy-confirmed data and implications for disease progression. Alzheimers Res Ther. 2023;15(1):41.","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"2239_CR20","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s11307-015-0924-7","volume":"18","author":"JY Choi","year":"2016","unstructured":"Choi JY, Lyoo CH, Lee JH, Cho H, Kim KM, Kim JS, et al. Human radiation dosimetry of [(18)F]AV-1451(T807) to detect tau pathology. Mol Imaging Biol. 2016;18(4):479\u201382.","journal-title":"Mol Imaging Biol"},{"issue":"11","key":"2239_CR21","doi-asserted-by":"publisher","first-page":"3797","DOI":"10.1007\/s00259-022-05822-9","volume":"49","author":"JP Wright","year":"2022","unstructured":"Wright JP, Goodman JR, Lin Y-G, Lieberman BP, Clemens J, Gomez LF, et al. Monoamine oxidase binding not expected to significantly affect [18F]flortaucipir PET interpretation. Eur J Nucl Med Mol Imaging. 2022;49(11):3797\u2013808.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2239_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-026-02983-x","volume":"151","author":"Y Chen","year":"2026","unstructured":"Chen Y, La Joie R, Pereira FL, Blazhenets G, Zhu L, Spina S, et al. Disentangling on and off-target binding in flortaucipir PET: a voxel-to-voxel P-tau, ferric iron, and MAO-B histology-to-flortaucipir PET comparison. Acta Neuropathol. 2026;151(1):21.","journal-title":"Acta Neuropathol"},{"issue":"19","key":"2239_CR23","doi-asserted-by":"publisher","first-page":"e1850","DOI":"10.1212\/WNL.0000000000207794","volume":"101","author":"EM Coomans","year":"2023","unstructured":"Coomans EM, de Koning LA, Rikken RM, Verfaillie SCJ, Visser D, den Braber A, et al. Performance of a [18F]flortaucipir PET visual read method across the Alzheimer disease continuum and in dementia with Lewy bodies. Neurology. 2023;101(19):e1850\u201362.","journal-title":"Neurology"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-026-02239-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-026-02239-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-026-02239-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:02:55Z","timestamp":1790643775000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-026-02239-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2239"],"URL":"https:\/\/doi.org\/10.1007\/s12149-026-02239-4","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"16 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors are employees of Eli Lilly Japan K.K. or Eli Lilly and Company and are minor shareholders of Eli Lilly and Company.","order":1,"name":"Ethics","label":"<b>Conflict of interest<\/b>","group":{"name":"EthicsHeading","label":"<b>Declarations<\/b>"}},{"value":"The studies were conducted in accordance with the principles of the Declaration of Helsinki, the International Council for Harmonisation (ICH) Good Clinical Practice (GCP) guidelines, the Code of Federal Regulations, and applicable laws and regulations. Written informed consent was obtained from all healthy volunteers and patients, and from caregivers\/guardians if applicable. Participants consented to the use of their data (including scans) for future research purposes.","order":2,"name":"Ethics","label":"<b>Ethical approval and consent to participate <\/b>","group":{"name":"EthicsHeading","label":"<b>Declarations<\/b>"}}]}}